North America Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Application (Drug Discovery, and Drug Development), By Function, By End User, By Country and Growth Forecast, 2024 - 2031

The North America Drug Discovery Informatics Market would witness market growth of 9.8% CAGR during the forecast period (2024-2031).

The US market dominated the North America Drug Discovery Informatics Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,741.7 million by 2031. The Canada market is experiencing a CAGR of 12.2% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 11.3% during (2024 - 2031).



By integrating data from multiple sources, including genomics, proteomics, transcriptomics, and metabolomics, informatics platforms enable researchers to comprehensively understand disease pathways, identify biomarkers, and prioritize potential drug targets for further investigation. Computational methods such as molecular modeling, virtual screening, and structure-activity relationship (SAR) analysis are pivotal in narrowing down vast chemical libraries to identify lead compounds with the greatest likelihood of success.

Furthermore, drug discovery informatics facilitates the assessment of pharmacokinetic and safety properties of lead compounds through in silico ADME-Tox prediction models, guiding compound selection and optimization early in the drug development process. These predictive tools help researchers identify potential risks and optimize compound structures to enhance efficacy, minimize toxicity, and improve overall drug candidate success rates.

In Mexico, cancer is a significant health concern, ranking as the third leading cause of death in the country. Over 195,000 new cancer cases were registered in 2020, with cervical, thyroid, colon, prostate, breast, and thyroid cancers being the most common. The nation reported 90,222 cancer-related fatalities in the same year, highlighting the urgent need for advancements in cancer treatment and drug discovery. The increasing incidence of cancer and the rising death rate from malignant tumors over the past decade underscore the importance of investing in drug discovery informatics to develop more effective and targeted therapies for cancer patients.

Mexico's National Council of Science and Technology (CONACYT) also plays a similar role in supporting R&D initiatives in healthcare, including those related to drug discovery informatics. CONACYT funds projects that contribute to Mexico's scientific and technological development, supporting innovation in the pharmaceutical industry. Hence, the market will expand rapidly in this region.

Based on Application, the market is segmented into Drug Discovery, and Drug Development. Based on Function, the market is segmented into Sequencing & Target Data Analysis, Molecular Modelling, Library & Database Preparation, Docking, and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Oracle Corporation
• Accenture PLC
• Thermo Fisher Scientific, Inc.
• Boehringer Ingelheim International GmbH
• Infosys Limited
• Charles River Laboratories International, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Certara, Inc.
• Jubilant Pharmova Limited

Market Report Segmentation

By Application

• Drug Discovery
• Drug Development

By Function

• Sequencing & Target Data Analysis
• Molecular Modelling
• Library & Database Preparation
• Docking
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America